BioCentury | Sep 21, 2017
Translation in Brief

Driving CARs into neuroblastoma

...Phase I/II testing for neuroblastoma. Juno Therapeutics Inc. (NASDAQ:JUNO)'s therapy targets L1 cell adhesion molecule ( L1CAM ; CD171...
BioCentury | Sep 19, 2016
Emerging Company Profile

Solid CARs

...for solid tumors, the most advanced of which, JCAR023 , targets L1 cell adhesion molecule ( L1CAM ; CD171...
...tumors and neuroendocrine tumors. Mount wouldn't comment on specific advantages of CLEC14A over targets like L1CAM...
BioCentury | Jul 13, 2015
Strategy

Celgene's Juno juggernaut

...and JCAR023 , an autologous CAR T cell therapy directed against L1 cell adhesion molecule ( L1CAM ; CD171...
BioCentury | Apr 27, 2015
Finance

CAR talk

...come from JCAR023 , a CAR T cell therapy that targets L1 cell adhesion molecule ( L1CAM ; CD171...
BioCentury | Sep 18, 2014
Distillery Therapeutics

Indication: Cancer

...information Cancer Pancreatic cancer L1 cell adhesion molecule (L1CAM; CD171) Studies in patient samples and mice suggest inhibiting CD171...
...help treat pancreatic cancer. In the vasculature of primary pancreatic cancers and other tumor types, CD171...
...compared with normal Cd171 expression or an inactive control IgG. Ongoing work includes testing the anti-Cd171...
BioCentury | Jul 21, 2008
Company News

Celltrion, Medigene, German Cancer Research Center deal

...license from the center to develop and commercialize a mAb against L1 cell adhesion molecule ( L1CAM , CD171...
Items per page:
1 - 6 of 6